84
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Cell membrane-cloaked bioinspired nanoparticles: a novel strategy for breast cancer therapy

ORCID Icon, , &
Pages 1351-1363 | Received 17 Nov 2022, Accepted 29 Apr 2023, Published online: 21 May 2023
 

Abstract

Breast cancer is one of the leading cause of death in women all around the world. Several strategies are utilized for treatment of breast cancer & its types. Nanotechnology is gaining interest due to its advantage of nano size, variety in the nano carriers, suitable for hydrophobic drug loading, controlled and site-specific delivery. Because of reproducible synthesis and features like size, shape, and ease of surface modification, nanoparticles are frequently chosen. Further, certain nanoparticles allow for adjuvant therapy, which results in a synergistic therapeutic outcome. Such nanoparticles, however, are frequently detected by the immune system and eliminated from the circulation. Cellular membranes have been studied extensively as potential alternatives for augmenting anticancer treatments’ biocompatibility and targeting abilities. Red blood cells (RBCs), cancer cells, platelets, and other cells have been identified as the sources of reported membrane-coated drug delivery systems. Each membrane’s distinct ability to target breast cancer tumors and biomarkers is exploited. Thus, inspired by nature the cell membranes are used to camouflage nanoparticles in blood circulation to improve retention time and tumor targeting ability. These cell membrane cloaked NPs (CMCNPs) are therefore being researched for theranoustic, photothermal therapy and vaccine development for breast cancer. Here, we have covered the crucial procedures and significant problems involved in the synthesis and characterization of CMCNPs. This thorough overview of modified CMCNPs for breast cancer discusses cell membrane cloaking techniques, as well as the prospects and limitations for clinical use in breast cancer.

Graphical abstract

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.